Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users.
| Title: | Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. |
|---|---|
| Authors: | Johnson EC; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.; Colbert SMC; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.; Jeffries PW; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.; Tillman R; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.; Bigdeli TB; Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Karcher NR; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.; Chan G; Department of Psychiatry, University of Connecticut, Farmington, CT, USA.; Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA.; Kuperman S; Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, USA.; Meyers JL; Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Nurnberger JI; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.; Plawecki MH; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.; Degenhardt L; National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.; Martin NG; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; Kamarajan C; Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Schuckit MA; Department of Psychiatry, University of California San Diego Medical School, San Diego, CA, USA.; Murray RM; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; Dick DM; Department of Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.; Edenberg HJ; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.; D'Souza DC; Department of Psychiatry, Yale University, New Haven, CT, USA.; Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA.; Di Forti M; Department of Social Genetics and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Mental Health Foundation Trust, London, UK.; Porjesz B; Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Henri Begleiter Neurodynamics Lab, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.; Nelson EC; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA.; Agrawal A; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. |
| Source: | Schizophrenia bulletin [Schizophr Bull] 2023 May 03; Vol. 49 (3), pp. 778-787. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0236760 Publication Model: Print Cited Medium: Internet ISSN: 1745-1701 (Electronic) Linking ISSN: 05867614 NLM ISO Abbreviation: Schizophr Bull Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2005- : Cary, NC : Oxford University Press; Original Publication: [Chevy Chase, Md., For sale by the Supt. of Docs., U. S. Govt. Print. Off. Washington] |
| MeSH Terms: | Schizophrenia*/epidemiology ; Schizophrenia*/genetics ; Cannabis*/adverse effects ; Alcoholism*; Humans ; Female ; Male ; Genetic Predisposition to Disease ; Risk Factors ; Multifactorial Inheritance |
| Abstract: | Background and Hypothesis: Risk for cannabis use and schizophrenia is influenced in part by genetic factors, and there is evidence that genetic risk for schizophrenia is associated with subclinical psychotic-like experiences (PLEs). Few studies to date have examined whether genetic risk for schizophrenia is associated with cannabis-related PLEs.; Study Design: We tested whether measures of cannabis involvement and polygenic risk scores (PRS) for schizophrenia were associated with self-reported cannabis-related experiences in a sample ascertained for alcohol use disorders (AUDs), the Collaborative Study on the Genetics of Alcoholism (COGA). We analyzed 4832 subjects (3128 of European ancestry and 1704 of African ancestry; 42% female; 74% meeting lifetime criteria for an AUD).; Study Results: Cannabis use disorder (CUD) was prevalent in this analytic sample (70%), with 40% classified as mild, 25% as moderate, and 35% as severe. Polygenic risk for schizophrenia was positively associated with cannabis-related paranoia, feeling depressed or anhedonia, social withdrawal, and cognitive difficulties, even when controlling for duration of daily cannabis use, CUD, and age at first cannabis use. The schizophrenia PRS was most robustly associated with cannabis-related cognitive difficulties (β = 0.22, SE = 0.04, P = 5.2e-7). In an independent replication sample (N = 1446), associations between the schizophrenia PRS and cannabis-related experiences were in the expected direction and not statistically different in magnitude from those in the COGA sample.; Conclusions: Among individuals who regularly use cannabis, genetic liability for schizophrenia-even in those without clinical features-may increase the likelihood of reporting unusual experiences related to cannabis use.; (© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.) |
| References: | Ethn Dis. 1996 Winter-Spring;6(1-2):1-8. (PMID: 8882831); Psychol Med. 2005 Dec;35(12):1795-803. (PMID: 16194282); Soc Psychiatry Psychiatr Epidemiol. 2019 Sep;54(9):1023-1044. (PMID: 31236631); Lancet Psychiatry. 2015 Mar;2(3):233-8. (PMID: 26359901); Psychol Addict Behav. 2017 Sep;31(6):664-675. (PMID: 28805408); Schizophr Bull. 2015 Mar;41(2):391-9. (PMID: 25031222); Alcohol Res Health. 2002;26(3):214-8. (PMID: 12875050); Biol Psychiatry. 2014 Jan 1;75(1):18-24. (PMID: 24135711); Psychol Bull. 1985 Jul;98(1):41-66. (PMID: 4034818); Biol Psychiatry. 2016 Apr 1;79(7):526-38. (PMID: 26970363); Nat Genet. 2022 May;54(5):573-580. (PMID: 35513724); Schizophr Bull. 2016 Sep;42(5):1262-9. (PMID: 26884547); Int J Epidemiol. 2007 Oct;36(5):1111-8. (PMID: 17726040); BMJ. 2002 Nov 23;325(7374):1212-3. (PMID: 12446537); Genes Brain Behav. 2019 Jul;18(6):e12579. (PMID: 31090166); Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):5-15. (PMID: 30671616); JAMA Psychiatry. 2019 Jan 1;76(1):87-94. (PMID: 30347017); Lancet. 1987 Dec 26;2(8574):1483-6. (PMID: 2892048); Nat Neurosci. 2018 Sep;21(9):1161-1170. (PMID: 30150663); Am J Med Genet. 1998 May 8;81(3):207-15. (PMID: 9603606); N Engl J Med. 1999 Feb 25;340(8):603-8. (PMID: 10029644); Transl Psychiatry. 2021 Apr 9;11(1):211. (PMID: 33837184); Int J Drug Policy. 2018 Jul;57:86-94. (PMID: 29709847); Addiction. 1999 Sep;94(9):1361-70. (PMID: 10615721); Arch Gen Psychiatry. 2004 Dec;61(12):1246-56. (PMID: 15583116); Am J Hum Genet. 2017 Apr 6;100(4):635-649. (PMID: 28366442); Cannabis Cannabinoid Res. 2018 Mar 01;3(1):85-93. (PMID: 29682608); JAMA Psychiatry. 2021 Oct 1;78(10):1143-1151. (PMID: 34347035); Proc Natl Acad Sci U S A. 1967 Jul;58(1):199-205. (PMID: 5231600); Mol Psychiatry. 2014 Nov;19(11):1201-4. (PMID: 24957864); Addiction. 2021 Nov;116(11):3227-3234. (PMID: 33950550); Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Jan;7(1):45-55. (PMID: 34271214); Nat Commun. 2019 Apr 16;10(1):1776. (PMID: 30992449); Neuropsychopharmacology. 2004 Aug;29(8):1558-72. (PMID: 15173844); JAMA Psychiatry. 2015 Jul;72(7):697-705. (PMID: 26018466); Br J Psychiatry. 2002 Feb;180:174-8. (PMID: 11823331); Schizophr Res. 2013 Aug;148(1-3):122-5. (PMID: 23806582); Br J Psychiatry. 1995 Mar;166(3):368-73. (PMID: 7788129); Schizophr Res. 2010 Jan;116(1):75-89. (PMID: 19897342); Alcohol Clin Exp Res. 2017 Feb;41(2):359-368. (PMID: 28073157); Lancet Psychiatry. 2020 Dec;7(12):1032-1045. (PMID: 33096046); Biol Psychiatry. 2016 Apr 1;79(7):549-56. (PMID: 26386480); Explor Med. 2021;2:60-73. (PMID: 34124712); Twin Res Hum Genet. 2020 Aug;23(4):221-227. (PMID: 32885772); J Stud Alcohol. 1994 Mar;55(2):149-58. (PMID: 8189735); Psychol Med. 2015 Nov;45(15):3181-9. (PMID: 26213314); Mol Psychiatry. 2016 May;21(5):608-14. (PMID: 26239289); Am J Psychiatry. 2012 Dec;169(12):1309-17. (PMID: 23212062); Schizophr Bull. 2021 Mar 16;47(2):517-529. (PMID: 33169155); J Natl Med Assoc. 1981 Jun;73(6):517-20. (PMID: 7241610) |
| Grant Information: | K23 MH121792 United States MH NIMH NIH HHS; K01 DA051759 United States DA NIDA NIH HHS; UL1 TR001863 United States TR NCATS NIH HHS; R01 DA054869 United States DA NIDA NIH HHS; N01HG65403 United States HG NHGRI NIH HHS; K02 DA032573 United States DA NIDA NIH HHS; R01 DA017305 United States DA NIDA NIH HHS; U10 AA008401 United States AA NIAAA NIH HHS |
| Entry Date(s): | Date Created: 20221222 Date Completed: 20230504 Latest Revision: 20240801 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10154717 |
| DOI: | 10.1093/schbul/sbac196 |
| PMID: | 36545904 |
| Database: | MEDLINE |
Journal Article